The world's first clinical trials for an mRNA-based lung cancer vaccine, BNT116, have commenced in the UK, involving 67-year-old Janusz Racz as the first recipient. Developed by BioNTech, the vaccine aims to treat non-small cell lung cancer (NSCLC) by training the immune system to recognize and attack cancer cells without harming healthy tissues, unlike traditional chemotherapy. Racz will receive multiple injections over 54 weeks as part of the trial that spans seven countries, including the US, Germany, and Spain, enrolling around 130 patients. The vaccine utilizes the same mRNA technology as the COVID-19 vaccines to target specific tumor markers, offering a highly targeted approach to treatment. Researchers hope this groundbreaking trial will significantly improve survival rates and become a new standard in cancer care.